While its presence was confirmed in France, the sub-variant of Omicron, BA.2.75 (also called Centaure) was particularly monitored.
With its 9 additional mutations in the spike protein of the Sras-CoV-2 virus, the BA.2.75 sub-variant is cause for concern. When he appeared in India at the beginning of July, the one who is now called “Centaur” by the authorities, showed a unique ability to escape natural immunity but also provided by vaccines and a previous infection. .
A Swedish study published at the end of July in prepublication on the BioRxiv platform looked at the famous Centaur subvariant that has been seen in 15 countries around the world since July 19.
The proposed study, which has not yet been peer-reviewed, sought to determine the level of subvariant neutralization of a panel of clinically relevant monoclonal antibodies as well as vaccines and prior infections.
The conclusion of the study has no appeal for its authors: “BA.2.75 does not show greater immune evasion than the current dominant BA.5” and “it shows a moderate sensitivity to tixagevimab and cilgavimab forming a cocktail of widely used monoclonal antibodies” .
Clearly, the initial concern was not confirmed and BA.2.75 should not be worse than BA.5. A BA.5 variant, however, was responsible for the 7th wave in France and which is considered “the worst virus known to date”. A wave in which contaminations are high but have no real impact on hospitalizations and deaths.
If a wave of BA.2.75 is excluded, it should not be much worse than BA.5. In addition, specialists say that they are now monitoring the mutations of BA.5 more closely, which seem to develop faster than BA.2.75 and which may have more significant consequences.